Zhu Ke-Wei
Office of Pharmacovigilance, Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd. Baiyunshan Pharmaceutical General Factory, Guangzhou 510515, China.
ACS Pharmacol Transl Sci. 2023 Aug 4;6(9):1306-1309. doi: 10.1021/acsptsci.3c00134. eCollection 2023 Sep 8.
Deuremidevir hydrobromide tablets and simnotrelvir tablets/ritonavir tablets (co-packaged) were approved by the Chinese National Medical Products Administration for the treatment of mild to moderate COVID-19 in January 2023. Both formulations contain small-molecule anti-SARS-CoV-2 agents. Deuremidevir, an oral nucleoside analog, is a broad-spectrum virus replication inhibitor targeting the highly conserved RNA-dependent RNA polymerase. Simnotrelvir-ritonavir is a co-packaged combination drug consisting of simnotrelvir tablets and ritonavir tablets. Simnotrelvir is an oral antiviral agent targeting the 3-chymotrypsin-like protease, which is essential for SARS-CoV-2 viral replication. Previous clinical trials revealed that both deuremidevir and simnotrelvir-ritonavir were effective and well tolerated in the treatment of COVID-19.
氢溴酸氘瑞米德韦片和先诺特韦片/利托那韦片（复方制剂）于2023年1月获得中国国家药品监督管理局批准，用于治疗轻至中度新型冠状病毒肺炎。两种制剂均含有小分子抗新型冠状病毒药物。氘瑞米德韦是一种口服核苷类似物，是一种针对高度保守的RNA依赖性RNA聚合酶的广谱病毒复制抑制剂。先诺特韦-利托那韦是一种由先诺特韦片和利托那韦片组成的复方组合药物。先诺特韦是一种口服抗病毒药物，作用于3-糜蛋白酶样蛋白酶，该蛋白酶对新型冠状病毒复制至关重要。先前的临床试验表明，氘瑞米德韦和先诺特韦-利托那韦在治疗新型冠状病毒肺炎方面均有效且耐受性良好。
